期刊文献+
共找到13篇文章
< 1 >
每页显示 20 50 100
一种简易的肠道脂酶抑制剂体内筛选方法 被引量:1
1
作者 冯芳 刘俊 丁志建 《中国药理学通报》 CAS CSCD 北大核心 2005年第4期509-509,共1页
关键词 肠道脂酶抑制 体内 筛选
下载PDF
肠道胆固醇吸收抑制剂Ezetimibe-一种新的降胆固醇药
2
《高血压杂志》 CSCD 2003年第5期403-403,共1页
关键词 肠道胆固醇吸收抑制 Ezetimib 降胆固醇药 药理机制 ApoE载脂蛋白
下载PDF
减肥药物最新研究进展 被引量:5
3
作者 钱磊 向华 +1 位作者 尤启冬 廖清江 《中国新药杂志》 CAS CSCD 北大核心 2007年第6期437-442,共6页
减肥药物按作用机制可分为3类:抑制食欲药物、抑制肠道消化吸收药物和增加能量消耗药物。现分别介绍上述各类中的代表性药物和正处于临床或临床前研究阶段、有开发前景的药物的最新研究进展。
关键词 减肥药物 抑制食欲药物 抑制肠道消化吸收药物 增加能量消耗药物
下载PDF
减肥药物最新研究进展
4
作者 赵瑞祥 《中国疗养医学》 2007年第11期694-695,共2页
减肥药物按作用机制可分为3类:抑制食欲药物和抑制肠道消化吸收药物与增加能量消耗药物。现分别介绍上述各类中的代表性药物和正处于临床前研究阶段、有开发前景药物的最新研究进展。
关键词 减肥药物 抑制食欲药物 抑制肠道消化吸收药物 增加能量消耗药物
下载PDF
想瘦,用药需慎重
5
作者 杨东运 《家庭医药(就医选药)》 2003年第10期47-47,共1页
快速的工作节奏,让都市女性们对运动和饮食减肥都有些望尘莫及,于是,她们把目光投向了药物减肥。然而,各式各样的减肥药品迷乱了她们的眼睛,如何比较,如何选择减肥药,成了她们关注的问题。现笔者就将目前主要的减肥药品种和各自的优缺... 快速的工作节奏,让都市女性们对运动和饮食减肥都有些望尘莫及,于是,她们把目光投向了药物减肥。然而,各式各样的减肥药品迷乱了她们的眼睛,如何比较,如何选择减肥药,成了她们关注的问题。现笔者就将目前主要的减肥药品种和各自的优缺点简介如下: 展开更多
关键词 减肥药 肥胖 抑制食欲类药物 抑制肠道消化吸收类药物 副作用 增加能量消耗类药物
下载PDF
新型抗肥胖药奥利司他 被引量:10
6
作者 齐绍康 袁捷 《中国新药杂志》 CAS CSCD 北大核心 2001年第6期423-425,共3页
新型抗肥胖药奥利司他 (Orlistat)是一种胃肠道脂酶抑制剂 ,能竞争性抑制约 1/ 3摄入脂肪的吸收 ,除了使体重减轻外 ,尚能使患者增高的血脂下降。由于未被吸收的饮食中脂肪的排出 ,其主要不良反应为腹泻与排出油样粪便。
关键词 奥利司他 肥胖 肠道脂酶抑制 脂肪吸收 血脂
下载PDF
联合降脂对急性冠状动脉综合征患者血脂及炎症标志物的影响 被引量:3
7
作者 苏庆丰 李喜梅 张林虎 《中国药物与临床》 CAS 2017年第11期1664-1666,共3页
血脂异常与冠心病的发生、发展有着非常密切的关系。他汀类药物降脂治疗已经成为临床冠心病防治中最重要的策略,其抑制动脉粥样硬化的进展主要得益于血脂的降低([1]),多项荟萃分析显示标准剂量的他汀治疗有约2/3的极高危患者血脂(LD... 血脂异常与冠心病的发生、发展有着非常密切的关系。他汀类药物降脂治疗已经成为临床冠心病防治中最重要的策略,其抑制动脉粥样硬化的进展主要得益于血脂的降低([1]),多项荟萃分析显示标准剂量的他汀治疗有约2/3的极高危患者血脂(LDL-C)不能达标([2]),大剂量的他汀治疗其降脂效果增加非常有限,而且肝功能异常及肌病发生率增加,使部分患者不能耐受。依折麦布是肠道胆固醇吸收抑制剂. 展开更多
关键词 急性冠状动脉综合征 血脂异常 降脂治疗 高危患者 炎症标志物 肠道胆固醇吸收抑制 他汀类药物 动脉粥样硬化
下载PDF
三谈速盛力饮品的保健医疗作用
8
作者 康学耕 尤静茹 《吉林农业》 2003年第10期36-37,共2页
速盛力(EM)饮品是众多特定有益微生物的混合物培养液.它是在日本EM公司和美国生物工程公司开发生产的EM原露的基础上,经我国科学家的研制开发而成的,由天意公司生产的高级菌品饮料.
关键词 速盛力饮品 保健医疗作用 自由基 排毒解毒作用 双歧杆菌 抑制肠道 灭杀病原菌
下载PDF
Esophageal space-occupying lesion caused by Ascaris lumbricoides 被引量:4
9
作者 Ping-Ping Zheng Bing-Yuan Wang +2 位作者 Fei Wang Ran Ao Ying Wang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第13期1552-1554,共3页
Ascaris lumbricoides is the largest intestinal nematode parasite of man,which can lead to various complications because of its mobility.As the esophagus is not normal habitat of Ascaris,the report of esophageal ascari... Ascaris lumbricoides is the largest intestinal nematode parasite of man,which can lead to various complications because of its mobility.As the esophagus is not normal habitat of Ascaris,the report of esophageal ascariasis is rare.An old female presented with dysphagia after an intake of several red bean buns and haw jellies.The barium meal examination revealed a spherical defect in the lower esophagus.Esophageal bezoar or esophageal carcinoma was considered at the beginning.The patient fasted,and received fluid replacement treatment as well as some oral drugs such as proton pump inhibitor and sodium bicarbonate.Then upper gastrointestinal endoscopy was done to further confirm the diagnosis and found a live Ascaris lumbricoides in the gastric antrum and two in the duodenal bulb.The conclusive diagnosis was ascariasis.The esophageal space-occupying lesion might be the entangled worm bolus.Anthelmitnic treatment with mebendazole improved patient's clinical manifestations along with normalization of the radiological findings during a 2-wk follow-up.Authors report herein this rare case of Ascaris lumbricoides in the esophagus,emphasizing the importance of awareness of this parasitic infection as it often presents with different and unspecific symptoms. 展开更多
关键词 ASCARIASIS Ascaris lumbricoides Esopha-gus ENDOSCOPE RADIOGRAPH
下载PDF
Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease
10
作者 Zuzana Zelinkova Evelien Bultman +3 位作者 Lauran Vogelaar Cheima Bouziane Ernst J Kuipers C Janneke van der Woude 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第47期6967-6973,共7页
AIM:To analyze sex differences in adverse drug reactions(ADR) to the immune suppressive medication in inflammatory bowel disease(IBD) patients.METHODS:All IBD patients attending the IBD outpatient clinic of a referral... AIM:To analyze sex differences in adverse drug reactions(ADR) to the immune suppressive medication in inflammatory bowel disease(IBD) patients.METHODS:All IBD patients attending the IBD outpatient clinic of a referral hospital were identified through the electronic diagnosis registration system.The electronic medical records of IBD patients were reviewed and the files of those patients who have used immune suppressive therapy for IBD,i.e.,thiopurines,methotrexate,cyclosporine,tacrolimus and anti-tumor necrosis factor agents(anti-TNF);infliximab(IFX),adalimumab(ADA) and/or certolizumab,were further analyzed.The reported ADR to immune suppressive drugs were noted.The general definition of ADR used in clinical practice comprised the occurrence of the ADR in the temporal relationship with its disappearance upon discontinuation of the medication.Patients for whom the required information on drug use and ADR was not available in the electronic medical record and patients with only one registered contact and no further followup at the outpatient clinic were excluded.The difference in the incidence and type of ADR between male and female IBD patients were analyzed statistically by χ 2 test.RESULTS:In total,1009 IBD patients were identified in the electronic diagnosis registration system.Out of these 1009 patients,843 patients were eligible for further analysis.There were 386 males(46%),mean age 42 years(range:16-87 years) with a mean duration of the disease of 14 years(range:0-54 years);578 patients with Crohn's disease,244 with ulcerative colitis and 21 with unclassified colitis.Seventy percent(586 pts) of patients used any kind of immune suppressive agents at a certain point of the disease course,the majority of the patients(546 pts,65%) used thiopurines,176 pts(21%) methotrexate,46 pts(5%) cyclosporine and one patient tacrolimus.One third(240 pts,28%) of patients were treated with anti-TNF,the majority of patients(227 pts,27%) used IFX,99(12%) used ADA and five patients certolizumab.There were no differences between male and female patients in the use of immune suppressive agents.With regards to ADR,no differences between males and females were observed in the incidence of ADR to thiopurines,methotrexate and cyclosporine.Among 77 pts who developed ADR to one or more anti-TNF agents,significantly more females(54 pts,39% of all anti-TNF treated women) than males(23 pts,23% of all antiTNF treated men) experienced ADR to an anti-TNF agent [P = 0.011;odds ratio(OR) 2.2,95%CI 1.2-3.8].The most frequent ADR to both anti-TNF agents,IFX and ADA,were allergic reactions(15% of all IFX users and 7% of all patients treated with ADA) and for both agents a significantly higher rate of allergic reactions in females compared with males was observed.As a result of ADR,36 patients(15% of all patients using anti-TNF) stopped the treatment,with significantly higher stopping rate among females(27 females,19% vs 9 males,9%,P = 0.024).CONCLUSION:Treatment with anti-TNF antibodies is accompanied by sexual dimorphic profile of ADR with female patients being more at risk for allergic reactions and subsequent discontinuation of the treatment. 展开更多
关键词 Adverse drug reactions Sexual dimorphism INFLIXIMAB ADALIMUMAB Inflammatory bowel disease
下载PDF
阿卡波糖治疗2型糖尿病的临床观察 被引量:3
11
作者 潘建新 《辽宁实用糖尿病杂志》 2003年第2期39-39,共1页
关键词 阿卡波糖 治疗 2型糖尿病 临床观察 副反应 肠道糖苷酶抑制
下载PDF
Distribution of secretory inhibitor of platelet microbicidal protein among anaerobic bacteria isolated from stool of children with diarrhea
12
作者 Iuri B Ivanov Viktor A Gritsenko 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第35期5428-5431,共4页
AIM: To study the secretory inhibitor of platelet microbicidal protein (SIPMP) phenotypes of faecal anaerobic isolates from patients with diarrhea.METHODS: Faecal isolates of anaerobic bacteria (B. fragilis, n = ... AIM: To study the secretory inhibitor of platelet microbicidal protein (SIPMP) phenotypes of faecal anaerobic isolates from patients with diarrhea.METHODS: Faecal isolates of anaerobic bacteria (B. fragilis, n = 42; B. longum, n = 70; A. israelii, n = 21; E. lentum, n = 12) from children with diarrhea were tested. SIPMP production was tested by inhibition of platelet microbicidal protein (PMP) bioactivity against B. subtilis and was expressed as percentage of inhibition of PMP bactericidal activity.RESULTS: Among anaerobic isolates 80% of B. longum strains, 85.7% of A. israeli/strains, 50% of E. lentum strains and 92.86% of B. fragilis strains were SIPMP-positive. The isolated anaerobic organisms demonstrated SIPMP production at a mean level of 13.8% ± 0.7%, 14.7% ± 1.8%, 3.9% ± 0.9% (P 〈 0.05) and 26.8% ± 7.5% (P 〈 0.05) for bifidobacteria, A. israelii, E. lentum and B. fragilis, respectively.CONCLUSION: Data from the present study may have significant implications in understanding the pathogenesis of microecological disorders in the intestine, as well as for future improvement in the prevention and therapy of anaerobe-associated infections. 展开更多
关键词 Platelet microbicidal protein Secretory inhibitor Anaerobic bacteria INTESTINE
下载PDF
Human intestinal acyl-CoA synthetase 5 is sensitive to the inhibitor triacsin C 被引量:3
13
作者 Elke Kaemmerer Anne Peuscher +4 位作者 Andrea Reinartz Christian Liedtke Ralf Weiskirchen Jürgen Kopitz Nikolaus Gassler 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第44期4883-4889,共7页
AIM:To investigate whether human acyl-CoA synthetase 5(ACSL5) is sensitive to the ACSL inhibitor triacsin C.METHODS:The ACSL isoforms ACSL1 and ACSL5 from rat as well as human ACSL5 were cloned and recombinantly expre... AIM:To investigate whether human acyl-CoA synthetase 5(ACSL5) is sensitive to the ACSL inhibitor triacsin C.METHODS:The ACSL isoforms ACSL1 and ACSL5 from rat as well as human ACSL5 were cloned and recombinantly expressed as 6xHis-tagged enzymes.Ni 2+-affinity purified recombinant enzymes were assayed at pH 7.5 or pH 9.5 in the presence or absence of triacsin C.In addition,ACSL5 transfected CaCo2 cells and intestinal human mucosa were monitored.ACSL5 expression in cellular systems was verified using Western blot and immunofluorescence.The ACSL assay mix included TrisHCl(pH 7.4),ATP,CoA,EDTA,DTT,MgCl 2,[9,103 H] palmitic acid,and triton X-100.The 200 μL reaction was initiated with the addition of solubilized,purified recombinant proteins or cellular lysates.Reactions were terminated after 10,30 or 60 min of incubation with Doles medium.RESULTS:Expression of soluble recombinant ACSL proteins was found after incubation with isopropyl betaD-1-thiogalactopyranoside and after ultracentrifugation these were further purified to near homogeneity with Ni 2+-affinity chromatography.Triacsin C selectively and strongly inhibited recombinant human ACSL5 protein at pH 7.5 and pH 9.5,as well as recombinant rat ACSL1(sensitive control),but not recombinant rat ACSL5(insensitive control).The IC50 for human ACSL5 was about 10 μmol/L.The inhibitory triacsin C effect was similar for different incubation times(10,30 and 60 min) and was not modified by the N-or C-terminal location of the 6xHis-tag.In order to evaluate ACSL5 sensitivity to triacsin C in a cellular environment,stable human ACSL5 CaCo2 transfectants and mechanically dissected normal human intestinal mucosa with high physiological expression of ACSL5 were analyzed.In both models,ACSL5 peak activity was found at pH 7.5 and pH 9.5,corresponding to the properties of recombinant human ACSL5 protein.In the presence of triacsin C(25 μmol/L),total ACSL activity was dramatically diminished in human ACSL5 transfectants as well as in ACSL5-rich human intestinal mucosa.CONCLUSION:The data strongly indicate that human ACSL5 is sensitive to triacsin C and does not compensate for other triacsin C-sensitive ACSL isoforms. 展开更多
关键词 Acyl-CoA synthetase 5 Fatty acid metabolism Mitochondria Triacsin C
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部